[{"indications": "Indications\u00a0see notes above", "name": "TOLVAPTAN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.5 Hypothalamic and pituitary hormones and anti-oestrogens", "6.5.2 Posterior pituitary hormones and antagonists", "Tolvaptan", "TOLVAPTAN"], "cautions": "Cautions\u00a0ensure adequate fluid intake (monitor\r\nfor dehydration in patients who are fluid-restricted); discontinue if rapid rise in serum sodium (greater\r\nthan 12\u00a0mmol/litre in 24 hours); diabetes\r\nmellitus; pseudohyponatraemia associated\r\nwith diabetes mellitus (exclude before treatment); interactions: Appendix 1 (tolvaptan)", "side-effects": "Side-effects\u00a0nausea, constipation, dry mouth; postural hypotension;\r\nthirst, decreased appetite, fever, asthenia; hyperglycaemia; urinary\r\nfrequency; hyperkalaemia, dehydration, ecchymosis, increased blood\r\ncreatinine; pruritus; less commonly taste disturbance; also reported hypernatraemia, hyperuricaemia, hypoglycaemia,\r\nsyncope, and dizziness", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/203991.htm", "doses": ["adult over 18 years, 15\u00a0mg\r\nonce daily, increased as required to max. 60\u00a0mg daily "], "pregnancy": "Pregnancy\u00a0avoid\u2014toxicity in animal studies"}]